Home Other Building Blocks (1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazol-4-yl)formamide

(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazol-4-yl)formamide

CAS No.:
1672-58-8
Catalog Number:
AG001X7K
Molecular Formula:
C12H13N3O2
Molecular Weight:
231.2505
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
250mg
95%
In Stock USA
United States
$122
- +
1g
95%
In Stock USA
United States
$300
- +
5g
95%
In Stock USA
United States
$1013
- +
Product Description
Catalog Number:
AG001X7K
Chemical Name:
(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1h-pyrazol-4-yl)formamide
CAS Number:
1672-58-8
Molecular Formula:
C12H13N3O2
Molecular Weight:
231.2505
MDL Number:
MFCD00085457
IUPAC Name:
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)formamide
InChI:
InChI=1S/C12H13N3O2/c1-9-11(13-8-16)12(17)15(14(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3,(H,13,16)
InChI Key:
WSJBSKRPKADYRQ-UHFFFAOYSA-N
SMILES:
O=CNc1c(C)n(n(c1=O)c1ccccc1)C
EC Number:
216-808-3
UNII:
63DKU1M0XK
NSC Number:
60565
Properties
Complexity:
359  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
231.101g/mol
Formal Charge:
0
Heavy Atom Count:
17  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
231.255g/mol
Monoisotopic Mass:
231.101g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
52.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0
Literature
Title Journal
High-performance liquid chromatographic assay for metamizol metabolites in rat plasma: application to pharmacokinetic studies. Journal of pharmaceutical and biomedical analysis 20121201
N-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)formamide. Acta crystallographica. Section E, Structure reports online 20110601
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters 20101101
Investigation of the microbial degradation of phenazone-type drugs and their metabolites by natural biofilms derived from river water using liquid chromatography/tandem mass spectrometry (LC-MS/MS). Water research 20100801
Hydrophilic anthropogenic markers for quantification of wastewater contamination in ground- and surface waters. Environmental toxicology and chemistry 20091201
Photodegradation study of three dipyrone metabolites in various water systems: identification and toxicity of their photodegradation products. Water research 20080501
Occurrence, fate and assessment of polar metamizole (dipyrone) residues in hospital and municipal wastewater. Chemosphere 20080401
Behaviour and redox sensitivity of pharmaceutical residues during bank filtration - Investigation of residues of phenazone-type analgesics. Chemosphere 20080401
Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. Critical care (London, England) 20080101
Investigation of the behavior and metabolism of pharmaceutical residues during purification of contaminated ground water used for drinking water supply. Chemosphere 20071101
[Analysis of three metabolite residues of dipyrone in bovine muscle and pork muscle using high performance liquid chromatography]. Se pu = Chinese journal of chromatography 20071101
Long-term comparison of trace organics removal performances between conventional and membrane activated sludge processes. Water environment research : a research publication of the Water Environment Federation 20061201
Simultaneous determination of residues of dipyrone and its major metabolites in milk, bovine muscle, and porcine muscle by liquid chromatography/mass spectrometry. Journal of AOAC International 20050101
Pharmaceuticals in the river Elbe and its tributaries. Chemosphere 20041001
Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. Liver 20021201
Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators. European journal of clinical pharmacology 20010901
Properties